You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Removing PFAS in Investigation Derived Wastes (IDW) with Electrocoagulation and Electrochemically Activated Persulfate

    SBC: AirLIft Environmental LLC            Topic: 19NCER3A

    Repeated use of aqueous firefighting foams containing per- and polyfluoroalkyl substances (PFAS) has contaminated hundreds of sites. To delineate the extent of contamination, many of these sites are undergoing intensive site investigations and generating large quantities of investigation derived wastes (IDW). Current disposal practices of landfilling or incineration are costly and burdensome. This ...

    SBIR Phase I 2020 Environmental Protection Agency
  2. CDK2 inhibitors for protecting hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Title: CDK2 inhibitors for protecting hearing loss PROJECT SUMMARY Hearing loss is a major health concern in our society, affecting over 360 million people worldwide (World Health Organization, 2017). Cisplatin chemotherapy causes permanent hearing loss in 40-60% of treated cancer patients. To date, no drugs have been approved by the Food and Drug Administration (FDA) for protection from cisplatin ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics PROJECT SUMMARYCisplatin is one of the most effective platinum-based compounds in the treatment of various types of malignancies, including head and neck, ovarian, and lung cancer. Despite its efficacy, ototoxcity, neurotoxicity, and nephrotoxicity stand out as the top three dose-limiting side effects of cisplatin chemothera ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. ProGel Technology for Better Management of Osteoarthritis Pain

    SBC: ENSIGN PHARMACEUTICAL, INC.            Topic: NIDA

    ABSTRACTAs one of the largest opioid consuming countries in the world, the prevalence of opioid use disorder (OUD) during 2017 is over 5 million in the U.S. alone. The significant increase of opioids use disorder (OUD) cases during the last 2 decades may be partially attributed to our overreliance on the prescription of the opioids for the management of non-cancer chronic pain, such as osteoarthri ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Video Monitoring Algorithm Development to Reduce Falls in Hospitals from Chair Exits

    SBC: OCUVERA LLC            Topic: NIA

    Project Summary The goal of the proposed SBIR project is to demonstrate the feasibility of developing custom algorithms to reduce the risk of falls associated with unassisted chair exits in hospital settings. The project will focus on predicting unassisted patient chair exits before they occur to provide nursing staff with additional lead time to address patient needs and prevent potential fall si ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Digital Monitoring System to Reduce Risk of Hospital-Acquired Pressure Injuries

    SBC: OCUVERA LLC            Topic: 600

    Project Summary/Abstract The goal of the proposed SBIR project is to develop, implement, and demonstrate the feasibility of a Digital Pressure Injury Monitoring (DPIM) system to reduce the risk of Hospital-Acquired Pressure Injuries (HAPIs). HAPIs are a common, costly, and serious problem for public health. Ocuvera’s DPIM system will use data from three-dimensional video processing and custom al ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutics to prevent aminoglycoside-induced hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    PROJECT SUMMARY Hearing loss is a major health concern in our society, affecting over 360 million people worldwide (World Health Organization, 2017). Aminoglycoside chemotherapy causes permanent hearing loss in 20-25% of treated patients. To date, no drugs have been approved by the Food and Drug Administration for protection from aminoglycoside-related hearing loss. Most candidate compounds curren ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Combinatorial Biomarkers for Malignant Polyps and Colon Cancer Detection

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 102

    ABSTRACT Technological advancements in colonoscopic and polypectomy procedures have drastically reduced both the incidence and overall mortality due to colorectal cancerCRCHowevereven with the availability of multiple screening toolsonlyof CRC are diagnosed at early stagein part due to lack of compliance with follow up colonoscopy procedurelimited access to colonoscopyThese factors contribute to i ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government